Company InfoNewsInvestor InformationResearchDevelopmentCareersBusiness DevelopmentResourcesDrugs databaseBack to the home pageSearch  
Drugs database
Drugs A-Z

Brands A-Z

Drugs by categories

Drugs by manufacturer

Drugs by packager

Antibiotics for sale

Online Viagra bestellen in Nederland

Home / Drugs / Starting with N / Neostigmine
 
Neostigmine
 

A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. [PubChem]
BrandsNeostigmine omega
Prostigmin
CategoriesParasympathomimetics
Cholinesterase Inhibitors
PackagersAmerican Regent
Pharmedium
Spectrum Pharmaceuticals
Valeant Ltd.

indication

Neostigmine is used for the symptomatic treatment of myasthenia gravis by improving muscle tone.

pharmacology

Neostigmine is a cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. By inhibiting acetylcholinesterase, more acetylcholine is available in the synapse, therefore, more of it can bind to the fewer receptors present in myasthenia gravis and can better trigger muscular contraction.

mechanism of action

Neostigmine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. The drug inhibits acetylcholinesterase which is responsible for the degredation of acetylcholine. So, with acetylcholinesterase inhibited, more acetylcholine is present By interfering with the breakdown of acetylcholine, neostigmine indirectly stimulates both nicotinic and muscarinic receptors which are involved in muscle contraction.. It does not cross the blood-brain barrier.

toxicity

Overdosage of Neostigmine can cause cholinergic crisis, which is characterized by increasing muscle weakness, and through involvement of the muscles of respiration, may result in death. The LD 50 of neostigmine methylsulfate in mice is 0.3 ± 0.02 mg/kg intravenously, 0.54 ± 0.03 mg/kg subcutaneously, and 0.395 ± 0.025 mg/kg intramuscularly; in rats the LD 50 is 0.315 ± 0.019 mg/kg intravenously, 0.445 ± 0.032 mg/kg subcutaneously, and 0.423 ± 0.032 mg/kg intramuscularly.

biotransformation

Neostigmine undergoes hydrolysis by cholinesterase and is also metabolized by microsomal enzymes in the liver.

absorption

Neostigmine bromide is poorly absorbed from the gastrointestinal tract following oral administration

half life

The half-life ranged from 42 to 60 minutes with a mean half-life of 52 minutes.

drug interactions

Dexamethasone: The corticosteroid, dexamethasone, may decrease the effect of the anticholinesterase, neostigmine.

Fludrocortisone: The corticosteroid, fludrocortisone, may decrease the effect of the anticholinesterase, neostigmine.

Hydrocortisone: The corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, neostigmine.

Prednisolone: The corticosteroid, prednisolone, may decrease the effect of the anticholinesterase, neostigmine.

Prednisone: The corticosteroid, prednisone, may decrease the effect of the anticholinesterase, neostigmine.

Triamcinolone: The corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, neostigmine.